The pattern of susceptibility to a range of antimicrobials was tested for 1485 isolates of Streptococcus pyogenes and 1547 isolates of Staphylococcus aureus included in the international PROTEKT (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin) surveillance study (1999)(2000). Overall, almost 10% of S. pyogenes isolates were erythromycin A resistant. There was a wide heterogeneity of resistance, with high levels of macrolide resistance in Poland (42%), Hong Kong (28%), Italy (25%), Portugal (24%) and Spain (21%), and no macrolide resistance in Indonesia, Austria, Belgium, the Netherlands or the UK. Using NCCLS tentative breakpoints, 97.6% of isolates were susceptible to telithromycin, with MIC 90 ≤ 0.015 mg/L in most regions. Resistance among S. pyogenes to the β-lactams (MIC 90 ≤ 0.12 mg/L for all except cefaclor) and fluoroquinolones was not detected. Macrolide resistance was present among the S. aureus isolates, and as with S. pyogenes, there was a wide heterogeneity of resistance, with lower rates in Australia, Indonesia, Hungary, Austria, Germany, the Netherlands, Portugal, Sweden and Switzerland. Methicillin-resistant isolates were resistant to the β-lactams and the macrolides. Resistance to telithromycin was detected in methicillin-resistant isolates in Latin and North America, Asia and Europe. Telithromycin resistance was nonexistent or low (MIC 90 range 0.06-0.25 mg/L) in Australia, Indonesia, Hungary, Austria, Germany, the Netherlands, Portugal, Sweden and Switzerland. Regardless of methicillin susceptibility, resistance to linezolid, teicoplanin or vancomycin was not apparent globally.
Introduction
Streptococcus pyogenes is one of the most common human pathogens. 1 It is implicated as the causative organism in many acute suppurative conditions, 2 including most cases of tonsillitis/pharyngitis in children, and severe life-threatening infections, including sepsis, necrotizing fasciitis and toxic shock syndrome. [3] [4] [5] Non-suppurative conditions such as rheumatic fever and acute glomerular nephritis are also caused by S. pyogenes. 6, 7 An increase in the incidence and severity of invasive infections caused by S. pyogenes has been reported in recent years. 2 Whilst S. pyogenes remains susceptible to penicillin G, patients with β-lactam-associated allergies tend to receive therapy with either erythromycin A or other macrolides. 8 However, a decrease in the susceptibility of S. pyogenes to the macrolides has been observed in several countries recently. [9] [10] [11] A survey of macrolide resistance phenotypes in isolates of S. pyogenes in Sweden revealed that strains constitutively resistant to macrolide, lincosamide and streptogramin B (MLS B ) agents were absent between 1980 and 1985 but accounted for 10% of isolates in 1986-1988. 10 Of 275 isolates of S. pyogenes from paediatric patients in Greece, 105 (38%) were macrolide-resistant with prevalence rates of 54% mef(A), 45% erm(A) subclass (TR) and 1% erm (B) . 12 A study evaluating the in vitro activity of seven antimicrobials against Gram-positive isolates in Belgium revealed that of 2014 group A streptococci tested, 131 (6.5%) were erythromycinresistant (MIC ≥ 1 mg/L). 1 A smaller study of 220 isolates from two centres in Italy revealed much higher resistance rates of between 43.5 and 51.2%. 2 The relationship between macrolide consumption and monoclonal spread of resistance Fax: +34-1-336-8809; E-mail: rcanton@hrc.insalud.es in S. pyogenes has been established, 13, 14 with results from studies in Spain and Slovenia showing a distinct correlation between erythromycin resistance in S. pyogenes and the total consumption of macrolides. 15, 16 Staphylococci, particularly Staphylococcus aureus, are a major cause of both hospital-and community-acquired infections. 17 The SENTRY surveillance programme has highlighted the prominence of S. aureus as an aetiological agent of bloodstream infection, skin and soft-tissue infection and pneumonia. [18] [19] [20] [21] [22] Data from the SENTRY programme also indicate that S. aureus is currently the most frequently isolated pathogen associated with bloodstream infections in the USA, Canada and Latin America, accounting for 22.6% of all bloodstream infections over a 12 month period. 21 Although S. aureus is implicated less frequently than Streptococcus pneumoniae, Haemophilus influenzae or Moraxella catarrhalis in community-acquired pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB), otitis media or sinusitis, it is a well-recognized cause of hospital-acquired pneumonia. S. aureus is particularly implicated in community-acquired infections in elderly patients. 23 Dramatic increases in the prevalence of methicillin-resistant S. aureus (MRSA) and coagulase-negative staphylococci with decreased susceptibility to multiple antimicrobials, may now be accompanied by a decreased utility of many currently licensed antimicrobials, including the fluoroquinolones. 24 Published reports from Japan, the USA and Europe also detail the emergence of multidrug-resistant S. aureus with reduced sensitivity to glycopeptides. 25, 26 In view of the traditionally empirical approach to the treatment of bacterial infections, particularly in the community setting, the increasing prevalence of streptococcal and staphylococcal resistance phenotypes should be taken into account when selecting the most appropriate antimicrobial therapy for a given infection. 23, 27 Research is underway to improve strategies of antimicrobial use and develop new agents that have a lower potential for induction or selection of resistance. Such research is of paramount importance in attempting to safeguard antimicrobial efficacy in the future. The ketolides are a new class of antimicrobial agents that have demonstrated clinical efficacy across a range of respiratory tract infections (RTIs) caused by streptococci and staphylococci, and have the potential both to overcome resistance and to minimize the potential for further resistance development.
PROTEKT (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin) was established to study the antimicrobial susceptibility of bacterial pathogens isolated from patients with community-acquired respiratory tract infections (CARTIs). This paper focuses on data gathered in the PROTEKT surveillance study on the current and increasing problem of decreased susceptibility of S. pyogenes and S. aureus to antimicrobial therapy.
Materials and methods

Collection centres
During the 1999-2000 winter season, 69 centres in 25 countries participated in PROTEKT: Canada (7), USA (8), Mexico (4), Brazil (7), Argentina (2), Germany (7), the Netherlands (1), Sweden (1), UK (2), Eire (1), Belgium (1), France (4), Portugal (2), Spain (2), Switzerland (2), Italy (2), Austria (1), Turkey (1), Hungary (1), Poland (1), Hong Kong (1), Japan (6), South Korea (2), Australia (2) and Indonesia (1).
S. pyogenes and S. aureus isolates
Each centre was requested to collect 25 isolates of S. pyogenes and 20 of S. aureus from community patients with sinusitis, otitis media, tonsillitis/pharyngitis, AECB or CAP. Patients with nosocomial RTIs and those with cystic fibrosis were excluded and duplicate strains or strains originating from existing collections were not included in the study. Demographic data and information on the source of the isolates were also collected. All isolates were transported to a central laboratory (GR Micro Ltd, London, UK) for microbiological investigation. Criteria for isolate storage, transportation and identification, and confirmation of isolate identification have been described in detail previously. 28 
Antimicrobial susceptibility testing
The susceptibility of all isolates was tested against the following antimicrobials: penicillin G, co-amoxiclav (2:1 ratio), cefaclor, cefixime, cefpodoxime, cefuroxime, azithromycin, clarithromycin, erythromycin A, telithromycin, clindamycin, levofloxacin, ciprofloxacin, moxifloxacin, co-trimoxazole (1:19 ratio), linezolid, quinupristin-dalfopristin (30:70 ratio), teicoplanin, tetracycline and vancomycin. Percentage susceptibilities were calculated based on breakpoints published by the NCCLS of the USA (Table 1) . It should be noted that NCCLS breakpoints applied to telithromycin are tentative and not yet approved.
MICs were determined using the NCCLS broth microdilution method 29 with lyophilized microtitre plates (Sensititre system, Trek Diagnostics) and an inoculum of 3-7 × 10 4 cfu in 100 µL medium. MIC endpoints were read as the lowest concentration of antibacterial that totally inhibited macroscopically visible growth of the inoculum.
Macrolide resistance was determined for S. pyogenes, and the presence of mechanisms for both MLS B (erm) and M-resistance (mef ) was analysed using a rapid-cycle multiplex polymerase chain reaction (PCR) method with probe detection.
Isolates of S. aureus were screened for methicillin resistance which is encoded by mecA, 24 using a standard oxacillin disc diffusion method.
Results
In total, 1485 isolates of S. pyogenes and 1547 isolates of S. aureus were submitted for inclusion in the PROTEKT database up to and including the year 2000. Western Europe accounted for most of the isolates of both pathogens (n = 499 and 462, respectively), followed by North America (n = 382 and 377, respectively), Latin America (n = 277 and 351, respectively), Asia (n = 202 and 222, respectively), Eastern Europe (n = 94 and 40, respectively) and Australasia (n = 31 and 95, respectively).
Antimicrobial resistance in S. pyogenes isolates
Regional and country-specific susceptibility data, including the percentages of S. pyogenes isolates susceptible, of intermediate susceptibility and resistant to representatives of the β-lactam, MLS, and fluoroquinolone classes of antimicrobials, are provided in Table 2 .
Overall, 9.6% of S. pyogenes isolates exhibited resistance to erythromycin A. The highest prevalences of macrolideresistant S. pyogenes isolates were observed in Asia (18.3%), Eastern Europe (10.6%) and Western Europe (9.8%). Within these regions, rates of resistance varied but were particularly high in Poland (41.7%), Hong Kong (28%), Italy (24.5%), Portugal (23.8%) and Spain (21.2%). Despite the high rates of macrolide resistance, susceptibility to telithromycin amongst S. pyogenes isolates remained high (using tentative NCCLS breakpoints): Poland (100%), Hong Kong (96%), Italy (79.6%), Portugal (83.3%) and Spain (98.1%). The prevalence of macrolide resistance was lower in Australia (4%), Turkey (1.9%), Sweden (4%), Switzerland (2.6%) and countries in both Latin America and North America, and was absent in Indonesia, Austria, Belgium, The Netherlands, and the UK. Overall, the prevalence of isolates demonstrating intermediate susceptibility to erythromycin A was low (0.13%). Only 0.07% of isolates were of intermediate susceptibility to telithromycin. Resistance among S. pyogenes to β-lactam and fluoroquinolone antimicrobials was not apparent. Table 3 provides MIC distribution data for isolates of S. pyogenes according to erythromycin A susceptibility phenotype. As expected, any increase in telithromycin MIC was confined to isolates of S. pyogenes expressing constitutive erythromycin A resistance. However, the numbers of erythromycin A-resistant strains were low and the prevalence of S. pyogenes isolates with reduced susceptibility to telithromycin was significantly lower. Decreases in susceptibility to telithromycin were most prominent in areas where resistance rates to erythromycin A were high: Asia, Western Europe and Eastern Europe. No resistance to telithromycin was observed in Australasia, Latin America or North America. Similarly, there were no reports of β-lactam or fluoroquinolone resistance. The genotypic basis of macrolide resistance amongst isolates of S. pyogenes is discussed elsewhere. 30 
Resistance of S. pyogenes according to erythromycin A susceptibility phenotype
Comparative susceptibility of S. pyogenes to commonly used antimicrobials
The comparative in vitro activities of various β-lactam, MLS and fluoroquinolone antimicrobials for S. pyogenes isolates tested in the PROTEKT study are shown in Table 4 . MIC distributions for the MLS class antimicrobials are shown in Figure 1 . Overall, resistance to the β-lactam antimicrobials, co-amoxiclav, cefaclor, cefixime, cefuroxime and penicillin G, was not observed, with MIC 90 values ≤0.12 mg/L for all agents except cefaclor. At the regional level, MIC 90 values indicated that the β-lactam antimicrobials were comparably effective overall and suggested that the most active β-lactam antimicrobial against S. pyogenes isolates was penicillin G.
The MIC 90 values for the commonly used MLS antimicrobials, such as azithromycin, clarithromycin and erythromycin A, suggest that in future, higher doses may be 
Antimicrobial resistance in S. aureus isolates
Regional and country-specific susceptibility data, including the percentage of S. aureus isolates susceptible, of intermediate susceptibility and resistant to telithromycin are provided in Table 5 . Overall, 80% of S. aureus isolates maintained susceptibility to telithromycin (using NCCLS tentative breakpoints). None of the isolates demonstrated resistance to teicoplanin or vancomycin. Decreased susceptibility to linezolid (MIC 8 mg/L) was noted in one isolate of S. aureus from the USA. At the regional level, the isolation of S. aureus with decreased susceptibility to telithromycin was more likely in Asia, Eastern Europe and Latin America. The prevalence rate of telithromycin-resistant S. aureus was nonexistent or very low in Australia, Indonesia, Hungary, Austria, Germany, the Netherlands, Portugal, Sweden and Switzerland (MIC 90 range 0.06-0.25 mg/L). Table 6 provides telithromycin resistance data for isolates of S. aureus according to the methicillin susceptibility phenotype. Resistance to telithromycin amongst methicillinsusceptible isolates of S. aureus was rare; however, fewer than 20% of the methicillin-resistant isolates maintained susceptibility to telithromycin as most of these isolates harboured constitutive MLS B resistance. Lack of susceptibility to telithromycin in S. aureus was most apparent in methicillin-resistant isolates from Latin America and Asia where over 96% exhibited resistance. Overall, there was no evidence of resistance to linezolid, teicoplanin or vancomycin regardless of methicillin susceptibility phenotype.
Resistance among S. aureus according to methicillin susceptibility phenotype
Comparative susceptibility of S. aureus to commonly used antimicrobials
MIC 90 values for linezolid, teicoplanin and vancomycin were comparable in all regions participating in the PROTEKT study, but suggested that teicoplanin was the most active of the antimicrobials tested against S. aureus (Table 7) . MIC distributions for the MLS B class of antimicrobials are shown in Figure 2 
Discussion
Results from the 1485 S. pyogenes and 1547 S. aureus isolates tested to date in the PROTEKT study support existing concerns over the increasing spread of resistance amongst common respiratory pathogens. 
S. pyogenes
The PROTEKT data indicated that overall, almost 10% of all S. pyogenes isolates were resistant to erythromycin A. There was a wide heterogeneity of resistance: relatively high levels of macrolide resistance in Asia, Eastern Europe and Western Europe, particularly in Hong Kong, Poland, Italy, Portugal and Spain, with lower levels in Australia, Turkey, Sweden, Switzerland, and both Latin and North America. Despite the high prevalence of erythromycin A resistance amongst isolates of S. pyogenes, susceptibility to the ketolide telithromycin remained high with very few strains overall exhibiting resistance (2.4%). In addition, resistance among S. pyogenes to either the β-lactams or fluoroquinolone antimicrobials was not apparent.
The data presented here suggest that decreased susceptibility to telithromycin appeared to be confined solely to isolates of S. pyogenes expressing erythromycin A resistance. However, the number of erythromycin A-resistant strains was low and the prevalence of S. pyogenes isolates with reduced susceptibility to telithromycin was commensurately lower making it difficult to draw conclusions. However, previously published data from Italy suggested high ketolide susceptibility in erythromycin A-resistant strains of S. pyogenes, 31 thus highlighting the need for further telithromycin susceptibility data on erythromycin A-resistant isolates in the community. However, it is probably important to consider the type of resistance in the strain under investigation. Resistance of streptococci to macrolide antimicrobials may be caused by either alteration in antimicrobial transport (efflux) or modification of the drug target (ribosomal binding site). MLS B resistance is defined as constitutive or inducible. Constitutively-resistant strains are always highly resistant and resistance extends to most MLS antibiotics. 10, 32 Almost all commercially available macrolides are strong inducers of methylase production and, therefore, of MLS B resistance in inducibly-resistant strains. 33 In inducibly-resistant S. pyogenes, expression of the relevant methylase is triggered by 14-and 15-membered lactone ring macrolides, 34 including erythromycin, clarithromycin, dirithromycin, oleandomycin, roxithromycin and azithromycin. Resistance to S. pyogenes may also be associated with the presence of a macrolide efflux system 35 (M phenotype), which is coded by a mef gene and confers cross-resistance to both 14-and 15-membered lactone ring macrolides. 2 Against erythromycin-resistant strains of S. pyogenes, ketolide antimicrobials appeared to be highly active when resistance is mediated by the efflux system, 35 and even more so when it is mediated by the methylase encoded by the erm(TR) gene. 36, 37 In contrast, the activity of the ketolides appears to be lower when resistance is mediated by the erm(B)-encoded methylases. 37
S. aureus
MLS B resistance was also detected in S. aureus isolates included in the PROTEKT study but overall, approximately 80% of isolates still retained susceptibility to telithromycin. At the regional level, these non-susceptible strains of S. aureus were most apparent in Asia, Eastern Europe, Latin America and North America. As with S. pyogenes, there was a wide heterogeneity of resistance, with rates being lower in Australia, Indonesia, Hungary, Austria, Germany, the Netherlands, Portugal, Sweden and Switzerland. Resistance of S.
aureus to telithromycin was more apparent in methicillinresistant isolates in Latin America and Asia, with high rates also in North America, Western Europe and Eastern Europe. However, resistance of S. aureus to linezolid and the glycopeptide teicoplanin was not detected, although low levels of intermediate susceptibility to linezolid were observed in the USA. Multidrug-resistant S. aureus strains have successively acquired a number of resistance determinants by acquisition of plasmids and transposons. 24 The mecA gene codes for the additional penicillin binding protein, PBP2a, which has a low affinity for all β-lactam antimicrobials, including methicillin. 38 The methicillin-resistant S. aureus isolates in the PROTEKT study were resistant to the β-lactams and the macrolides. The ketolide telithromycin was comparatively the most active of this group, maintaining an MIC 50 of 0.06 mg/L against all isolates tested, although those isolates harbouring constitutive MLS B resistance were resistant to this agent also. Vancomycin remains the treatment of choice for severe multidrug-resistant staphylococcal infections, 17 and the PROTEKT data indicate that susceptibility was maintained among community isolates.
While adding to the increasing evidence available on the widespread resistance of CARTIs, the PROTEKT data are suggestive that currently available empirical treatments will no longer be sufficiently effective in the future. These worrying data highlight the need for increased vigilance in monitoring and for tracking changes in antimicrobial susceptibility to promote successful clinical therapy, maintain the utility of current agents and assist in the development of new therapeutic strategies. The results of the PROTEKT study and other similar programmes should be used to promote rational prescribing, by guiding clinicians in choosing the most appropriate antimicrobial for the treatment of CARTIs in their 
